What is spinal muscular atrophy (SMA)?
Spinal muscular atrophy is a genetic disease that affects the motor nerve cells in the spinal cord, resulting in progressive muscle wasting and weakness. It typically begins in infancy or childhood years and affects about 1 in 11,000 babies.
What causes spinal muscular atrophy?
SMA is an autosomal recessive disease. This means that both males and females are equally affected, and that changes or mutations in two copies of the SMN1 gene (typically, one inherited from each parent), are necessary to have the condition. About 1 in every 50 Americans is a carrier for SMA.
Testing for SMA is done by looking for deletions (in nearly 95 percent of cases of SMA) or in a smaller number of cases looking for mutations in the SMN1 gene. Symptomatic individuals of all ages can be tested through DNA studies typically done from a blood sample. In addition, in some cases, prenatal testing can identify expecting parents who are at risk of having a child with SMA, and when desired, further fetal testing can be done. When both parents are carriers, there is a one in four, or 25 percent, chance, with each pregnancy, to have a child with SMA.
What are the symptoms of spinal muscular atrophy?
Spinal muscular atrophy is sometimes difficult to diagnose, as symptoms can resemble other conditions or medical problems. Each child may experience symptoms differently but all children show signs of weakness that gradually worsens over time, without signs of cognitive delay. There are four types of spinal muscular atrophy based on symptoms and age of onset. The child may have the following symptoms in the natural history of disease (or untreated form):
- Type I (also called Werdnig-Hoffman or infantile-onset SMA). This is the most severe type of SMA and may be present at birth or in the first six months of life. Infants have problems holding their head, sucking, feeding, swallowing and typically move very little. Symptoms may not have been apparent right at birth and can become more evident within the first few months of life, and gradually progress. The muscles of the chest are also affected and can impact breathing. The motion of the tongue is described as having "worm-like" movements (also known as fasciculations). Death results usually by the age of two to six years from breathing problems. Children with SMA type I often require additional support for breathing and nutrition.
- Type II. The onset of this form of SMA is typically seen in children from six months to 18 months of age. They typically have generalized muscle weakness, and although they are able to maintain independent sitting when placed, have difficulty transitioning into sitting and are more likely to crawl on their bellies than on hands and knees. By definition, these children clinically do not achieve independent standing (in the natural history of the disease when untreated). As the disease progresses, children with SMA type II can also be at risk for feeding difficulties, breathing problems (especially in sleep or with illness) and orthopedic problems (such as contractures, scoliosis and hip dislocation).
- Type III (also called Kugelberg-Welander or juvenile SMA). This form of SMA affects children older than 18 months of age or as late as adolescence. These children have measurable muscle weakness and may show signs of clumsiness early and then progress to having difficulty walking, standing up or climbing stairs.These children will typically live long into their adult years. The frequency of feeding or respiratory difficulties in this group is smaller compared to individuals with SMA type I or type II.
- Type IV. This form of SMA typically affects adults in their thirties and fourties, resulting in walking difficulty and easy fatigability.
The symptoms of SMA may resemble other problems or medical conditions. Always consult your child's doctor for a diagnosis. If SMA is suspected or there is unexplained weakness or low tone, you should be referred for further evaluation by a neurologist (preferably one with expertise in the evaluation of children with neuromuscular disease).
How is spinal muscular atrophy diagnosed?
The diagnosis of spinal muscular atrophy is made after the sudden or gradual onset of specific symptoms associated with progressively increasing weakness and after diagnostic testing. During the physical examination, your child's doctor will obtain a complete medical history of your child, and he or she may also ask if there is a family history of any medical problems.
Diagnostic tests that may be performed to confirm the diagnosis of spinal muscular atrophy include the following:
- Genetic tests: diagnostic tests that evaluate for conditions that have a tendency to run in families.
- Blood tests
- Muscle biopsy: a small sample of the muscle is removed and examined to determine and confirm a diagnosis or condition.
- Electrodiagnsotic Studies (EMG/ nerve conduction study): A test that measures the electrical activity of nerves, and also measures a muscle or a group of muscles and the function of the associated nerves. An EMG can detect abnormal electrical muscle activity due to diseases and neuromuscular conditions.
When there is a known family history, or if parents are known to be carriers, testing may be done earlier. Some families will undergo prenatal testing including genetic testing during the pregnancy to determine if the fetus is affected. Testing can also be done after birth in the newborn to determine if the baby is affected with SMA, even before symptoms begin.
Now that there are treatment options available, it is important to test for SMA as soon as it is suspected or if there is a family history (or parents are known carriers), because earlier treatment is better for motor function.
Treatment of spinal muscular atrophy
Specific treatment for spinal muscular atrophy will be determined by your child's doctor based on:
- Your child's age, overall health and medical history
- The extent of the condition
- The type of spinal muscular atrophy
- Your child's tolerance for specific medications, procedures or therapies
- Your child’s ability to function compared to his/ her peer group
- Expectations for the course of the condition
- Your opinion or preference
The key to medically managing spinal muscular atrophy is through early detection.
There are new therapies for patients with spinal muscular atrophy, with the first FDA approved treatment (approved December 2016) and new treatments in clinical trials. The FDA approved drug for SMA is called Spinraza (Nusinersen) and it is a medication that is given into the spinal fluid space (through a spinal tap procedure). Our team at Children’s National is proud to be able to offer this treatment to our patients with SMA. We have a large program at Children’s National both for treatment and for close monitoring and systematic clinical follow up pre- and post- initiation of treatment. While a treatment may improve, slow down or halt the disease, it may not completely prevent aspects of the disease from occurring. Therefore, there is still a role for close multi-disciplinary follow up to manage other issues that can arise in children and young adults with SMA.
Respiratory: With the close follow up of a pulmonologist, we will assess your child’s breathing function. Some children may require assistance during times of illness (for example cough assist, suctioning or nebulizer treatments). Some children may require additional support for breathing in sleep or during naps (eg: BiPAP). Other children may have more severe respiratory difficulty and may require a breathing machine to help the child breathe easier. Children may need more close monitoring and evaluation during times of respiratory illness.
Feeding/ Communication: We monitor a child’s ability to feed and swallow very closely to assess for risk of choking or aspiration. We also monitor the weight of our patients to determine if they are getting enough calories when fed orally, or if they require some additional assistance (eg: caloric supplementation or use of a feeding tube for supplementation). A speech therapist in our program also monitors a child’s language and communication skills and refers for ongoing outpatient therapies or communication strategies when indicated.
Musculoskeletal/ Orthopedic: Our neuromuscular, physical medicine and rehabilitation, physical therapy and orthopedics teams work jointly to determine your child’s needs. This may include regimens for therapy, stretching programs, bracing, equipment for mobility and transfers and in some cases surgery (eg: scoliosis). Our team also works to track motor function and neurologic function over time.
Our SMA Care Center at Children’s National is under the co-directorship of Sarah (Sally) Evans, M.D., and Diana Bharucha-Goebel, M.D., and coordination of Kathleen Smart. We are proud to be designated as one of the first Cure SMA Care Center Network sites in the United States. Our team is committed to providing up to date, personalized, comprehensive and cutting-edge treatments and care for our patients. We closely serve as a resource for our patients and their families when engaging with their schools, community therapists and inpatient care teams during hospitalizations.